Advertisement


Lisa Carey, MD, and Kathy Albain, MD, on Results of the SWOG-8814 Trial

2015 San Antonio Breast Cancer Symposium

Advertisement

Lisa A. Carey, MD, of the University of North Carolina, and Kathy S. Albain, MD, of Loyola University Medical Center, discuss molecular predictors of outcome on adjuvant CAF plus tamoxifen, vs tamoxifen in postmenopausal patients with estrogen receptor–positive, node-positive breast cancer (Abstract S3-02).



Related Videos

Breast Cancer

Matthew J. Ellis, PhD, FRCP: Update on Translational Research

Matthew J. Ellis, PhD, FRCP, of the Baylor College of Medicine, gives his expert perspective on this evolving area of research.

Breast Cancer

Sarat Chandarlapaty, MD, PhD, on BOLERO-2 Clinical Trial Results

Sarat Chandarlapaty, MD, PhD, of the Memorial Sloan Kettering Cancer Center, discusses results from this study that showed patients with ER-positive metastatic breast cancer who had a D538G and/or a Y537S mutation in the ESR1 gene had significantly worse median overall survival (Abstract S2-07).

Breast Cancer

Andrew Seidman, MD, and Eric Winer, MD, on Triple-Negative Breast Cancer: Results of the CALGB Alliance Trial

Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Eric P. Winer, MD, of the Dana-Farber Cancer Institute, discuss the results of this study that showed pathologic complete response to presurgery chemotherapy improved survival (Abstract S2-05).

Breast Cancer

Hans Wildiers, MD, PhD on the TH3RESA Study: Final OS Results

Hans Wildiers, MD, PhD, of the University Hospitals, Leuven, discusses this phase III study on the use of ado-trastuzumab emtansine vs treatment of physician’s choice in previously treated HER2-positive metastatic breast cancer (Abstract S5-05).

Breast Cancer

Clifford Hudis, MD, and Julia White, MD, on Early-Stage Breast Cancer: Hypofractionated Radiotherapy

Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, and Julia R. White, MD, of Ohio State University Comprehensive Cancer Center, discuss a meta-analysis on efficacy and safety of hypofractionated radiotherapy for the treatment of early-stage breast cancer (Abstract P3-12-15).

Advertisement

Advertisement



Advertisement